Metabolomics of Esophageal Squamous Cell Carcinoma Tissues: Potential Biomarkers for Diagnosis and Promising Targets for Therapy

Figure 10

Plot of ROC curve analysis for 13 significant differential metabolites. (a–m) [(a) cytochalasin Ppho; (b) PE (15:0/20:1(11Z)); (c) methyl 9,10-epoxy-12,15-octadecadienoate; (d) oleoyl glycine; (e) dextrorphan O-glucuronide; (f) butyl (S)-3-hydroxybutyrate glucoside; (g) (R)-1-O-[b-D-apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol; (h) 2-amino-5-phenylpyridine; (i) Cer (t18:0/16:0(2OH)); (j) janthitrem G; (k) PI (20:0/20:4(5Z,8Z,11Z,14Z)); (l) ganglioside GA2 (d18:1/9Z-18:1); (m) 13-hydroxy-5-O-methylmelledonal]. Note: The -axis is 1-specificity; -axis is sensitivity; the point indicated on the curve is the optimal critical value; the “bar” on the point is the corresponding point confidence interval of specificity and sensitivity; AUC indicated in the figure is the area under the corresponding curve.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)